Form 4: Cytokinetics Director Robert Landry Receives Equity Grant
Statement of Changes in Beneficial Ownership
Director Robert E. Landry acquired 2,851 shares of common stock and 4,301 stock options in Cytokinetics, Inc.
Summary
- Director Robert E. Landry was granted 2,851 shares of common stock at a price of $0.
- Director Robert E. Landry was granted 4,301 non-qualified stock options with an exercise price of $77.15.
- The stock options vest starting June 27, 2026, and expire on May 26, 2036.
- Following these transactions, the director holds 10,184 shares of common stock directly.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Alignment of director interests with shareholders through equity-based compensation.
Negatives
- Dilutive effect of new equity grants to insiders.
Risks
- Market volatility affecting the value of equity-based compensation.
- Potential for future dilution of existing shareholder value.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on director compensation.
Industry Context
StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and shareholders.
Comparison to Industry Standards
- The grant of stock options and restricted stock units is consistent with standard compensation packages for directors in mid-cap biopharmaceutical companies.
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Options become exercisable on June 27, 2026.
Key Dates
| Date | Description |
|---|---|
| 05/26/2036 | Expiration date of the granted stock options. |
| 05/27/2026 | Date of the reported equity transactions. |
| 06/27/2026 | Date the granted stock options become exercisable. |
Keywords
Cytokinetics, CYTK, Form 4, Insider Trading, Equity Compensation, Director Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.